This report provides an overview of the Japanese CMO (contract manufacturing organization) market. Readers will get insights about related regulations, market size, major players, and future prospect in this industry.
The 2013 CMO market reached approximately 290 billion Yen, with over 5% increase from the previous year.
While most of products outsourced from pharma are long listed drugs, we also see expanding demands for new drugs, investigational products, and generics these days.
The outsourcing rate is steadily rising. Currently, 30% of pharmaceutical productions seem to be outsourced to 3rd parties such as CMO.
We expect the convergence into large size of CMOs in the future. CMOs with large scale and capability will survive over time. Considering the market immaturity in Japan, we anticipate low move, but we will see further M&A over time.
Japanese CMOs remain competitive, with local capability and facilities. Non Japanese CMOs will continue to struggle, unless they invest on local operations and securing high level of quality control.
On the other hand, we will see more market erosion from pharma, especially generic companies into CMO business. As they have larger advantage with regards to customer base and capability, we expect generic companies will become the game changers, unless CMOs become large enough soon.
- Definition of CMO
- Laws and Regulations Related to CMOs
- Main Industry Group
- CMO Market Scale
- Main CMOs
- Nipro Pharma
- Bushu Pharmaceuticals
- CMIC CMO
- Catalent Japan
- Other CMOs
- Outsourcing Trend from Pharma
- Trend of pharmas’ selling/closing Factories
- Market Entry from Drug makers
- Future Prospects
- Appendix: Quick Look of global CMO Market